| 27.3881 2.388 (9.55%) | 10-15 12:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 37.78 | 1-year : | 44.13 |
| Resists | First : | 32.34 | Second : | 37.78 |
| Pivot price | 27.58  |
|||
| Supports | First : | 21.09 |
Second : | 14.14 |
| MAs | MA(5) : | 27.14  |
MA(20) : | 25.95 |
| MA(100) : | 13.56 |
MA(250) : | 11.42 |
|
| MACD | MACD : | 2.8 |
Signal : | 3.4 |
| %K %D | K(14,3) : | 45 |
D(3) : | 52.6 |
| RSI | RSI(14): 63.1 |
|||
| 52-week | High : | 32.34 | Low : | 5.66 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RAPT ] has closed above bottom band by 49.9%. Bollinger Bands are 23.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 26.29 - 26.44 | 26.44 - 26.56 |
| Low: | 24.41 - 24.61 | 24.61 - 24.76 |
| Close: | 24.73 - 25.03 | 25.03 - 25.26 |
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Wed, 15 Oct 2025
What hedge fund moves indicate for RAPT Therapeutics Inc. (0RA) stock - Weekly Stock Analysis & Daily Price Action Insights - newser.com
Wed, 15 Oct 2025
Risk adjusted return profile for RAPT Therapeutics Inc. analyzed - Global Markets & Accurate Trade Setup Notifications - newser.com
Wed, 15 Oct 2025
What indicators show strength in RAPT Therapeutics Inc. - Weekly Trend Recap & Fast Entry Momentum Alerts - newser.com
Mon, 13 Oct 2025
Barclays Initiates Coverage of RAPT Therapeutics (RAPT) with Overweight Recommendation - Nasdaq
Fri, 10 Oct 2025
RAPT Therapeutics: Anticipated Catalysts and Growth Potential Drive Buy Rating - TipRanks
Mon, 29 Sep 2025
RAPT Therapeutics Announces FDA Clearance of IND - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 102.5 (%) |
| Shares Short | 500 (K) |
| Shares Short P.Month | 427 (K) |
| EPS | -14.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.93 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46.3 % |
| Return on Equity (ttm) | -77.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -92 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -1.87 |
| PEG Ratio | 0 |
| Price to Book value | 2.77 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|